BTBenoit Tressieres

Benoit Tressieres

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benoit Tressieres has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Activation of Platelet Caspase‐1 and P‐Selectin Over‐Expression in Sickle Cell Disease Patients: An Involvement of NLRP3 Inflammasome?

    by Livia Claude, Frédéric Martino, Lydiane Mordier, Doris Célanie, Emmanuelle Bernit, Maryse Etienne‐Julan, Benoît Tressières, Marc Romana, Véronique Baccini

    Sickle cell disease (SCD) is characterized by hemolytic anaemia, painful vaso‐occlusive crises, and chronic inflammation resulting partly from platelet activation. It has been shown that platelets express the nucleotide‐binding domain leucine‐rich repeat containing protein 3 (NLRP3) and the apoptosis‐associated speck‐like protein containing a CARD (ASC), forming the NLRP3 inflammasome, which controls activation of caspase‐1 and cleavage of interleukin‐1β (IL‐1β). Bruton tyrosine kinase (BTK), known to activate the NLRP3 inflammasome, is also expressed in platelets. In SCD, platelets are activated and can secrete increased quantities of IL‐1β, suggesting a possible activation of the NLRP3 inflammasome. Here, we assessed platelet P‐selectin expression, caspase‐1 activation, platelet–neutrophil aggregate formations by flow cytometry and BTK phosphorylation by Western blot in a cohort of 81 adult SCD patients at steady state condition (34 SC and 47 SS patients). We showed an increase in platelet activation in sickle patients and a high level of platelet–neutrophil aggregate in SS patients compared to healthy subjects (17 AA). We also demonstrated platelet caspase‐1 activation in SCD patients and obtained data suggesting for the first time NLRP3 inflammasome activation in SC patients. Further studies are needed to understand the mechanism of caspase‐1 activation and evaluate the potential therapeutic efficiency of Ibrutinib, a BTK inhibitor.

  • Higher serum uric acid associates with better cognitive performance and survival in Caribbean parkinsonism

    by Tanicia Mameri, Regine Edragas, Annick Chavonnet, Benoit Tressieres, Loic Dragin, Angela Lackmy, Véronique Pelonde-Erimee, Stanie Gaete, Regine Hierso, Pierre Pouget, et al.

  • Peripheral Immunological Signatures of Parkinsonism: Insights from the Caribbean vs. North America

    by Hugo Chaumont, Perrine Coquelet, Renaud Balthazard, Benoit Tressières, Juliette Quéau-Chaumont, Sylvie Ravion, Stanie Gaëte, Ariane Veilleux Carpentier, Antoine Duquette, Lovatiana Andriamboavonjy, et al.

    The contribution of the peripheral immune system to Parkinson's disease (PD) and Atypical parkinsonism (AP), including multiple system atrophy, progressive supranuclear palsy, and Caribbean atypical parkinsonism, is increasingly recognized, albeit incompletely resolved. Our study aimed to compare the peripheral immunological profile of PD and AP patients from two distinct geographical areas, Guadeloupe and Montreal. We conducted a cross-sectional study on PD and AP patients and healthy controls from Guadeloupe and Montreal (total 57 subjects). We collected clinical assessments and arbovirus serologies. We performed an immune profiling of peripheral blood mononuclear cells by flow cytometry. Nearly all Guadeloupe subjects had prior exposure to an endemic arbovirus, while seropositivity was minimal in Montreal. Samples from the Guadeloupe cohort showed an increased proportion of γδ T cells and enhanced CD8+ T cell inflammatory properties, particularly in PD patients and healthy controls, compared to their Montreal counterparts. Specific memory B cell subsets were more abundant in Guadeloupe-PD and Guadeloupe-AP than in Montreal patients. The percentage of plasmablasts positively correlated with clinical scores in Guadeloupe-PD and AP patient groups. Montreal-AP patients displayed elevated monocyte percentages; proportions of monocytes and classical monocytes correlated with clinical scores in this patient group. Our study highlights immune differences related to disease type (PD vs. AP) and geographical location (Guadeloupe vs. Montreal), particularly in AP patients. A better understanding of the impact of environmental factors and age-related changes on the peripheral immune system of PD and AP patients could provide essential information to slow down and treat these conditions. Graphical Abstract The alternative text for this image may have been generated using AI.

  • Open Access

    Atypical parkinsonian syndromes in French Guiana: Similarities and differences with Caribbean variants

    by Amina Nasri, Hugo Chaumont, Souraya Arnaud, Benoit Tressieres, Mamadou Sow, Angéla Lackmy, Régine Edragas, Mathieu Nacher, Bertrand de Toffol, Emmanuel Roze, et al.

    Background: Atypical parkinsonian syndromes are highly prevalent in the French West Indies (FWI), making up 70% of degenerative parkinsonisms and including “Caribbean Atypical Parkinsonism”. Environmental neurotoxins from Annonaceae plants are implicated. Despite close ties, parkinsonism data for French Guiana remain limited. Objective: This study aimed to compare atypical parkinsonism frequencies between French Guiana and FWI, assess clinical characteristics in French Guiana, and evaluate potential environmental toxin exposure. Methods: Degenerative parkinsonism patients were recruited from a community-based population in French Guiana and compared with a FWI cohort. Results: Among 372 patients (67 from French Guiana, 305 from FWI), atypical parkinsonian syndromes accounted for 41.8% in French Guiana, lower than in FWI (66.2%, p < 0.001). In French Guiana, these syndromes were more common in males (sex-ratio: 3 vs. 1.22 in FWI, p = 0.044; adjusted p-value = 0.281) and often involved cerebellar symptoms (p < 0.001). Cases not fitting classical subtypes were classified as “other atypical parkinsonian syndromes” (35.7% in French Guiana, 41.6% in FWI), with a supranuclear palsy-like phenotype often presenting with additional rapid eye movement (REM) sleep behavior disorder, hallucinations, or orthostatic hypotension. Annonaceae consumption was higher in FWI (93%) than in French Guiana (79.2%, p < 0.001), while alcohol use was more common in French Guiana (p = 0.005). Conclusions: Atypical parkinsonism in French Guiana resembles that in FWI but is less common, with an intermediate prevalence between Caucasian and Caribbean populations. Shared environmental factors, such as Annonaceae exposure, may contribute to this presentation, supporting the term “Caribbean Atypical Parkinsonism” for both regions.


  • Open Access

    Overweight and Obesity in People Living With Type 1 Diabetes: A Cross‐Sectional Analysis of the BETTER Registry

    by Marie‐Laure Lalanne‐Mistrih, Anne Bonhoure, Virginie Messier, Valérie Boudreau, Maha Lebbar, Meryem K. Talbo, Cathy J. Sun, Aude Bandini, Laurence Secours, Virginie Calderon, et al.

    Aims: The prevalence and associations of overweight and obesity in Canadian adult people living with type 1 diabetes (PWT1D) are poorly documented. In a cohort of PWT1D patients, this study assesses (i) overweight and obesity frequencies and associated PWT1D clinicodemographic characteristics, (ii) diabetes characteristics, and (iii) the use of noninsulin adjunctive agents.Materials and Methods: Cross‐sectional analysis of self‐reported data from the BETTER registry: 1091 adult PWT1D (aged 44.4 ± 15.0 years; 32% HbA1cp < 0.001). Compared to other PWT1D, those living with obesity reported higher HbA1c (p < 0.05), less frequent hypoglycemia (p < 0.05), more cardiovascular diseases (p < 0.003), retinopathy, neuropathy, depression treatment as well as noninsulin adjunctive agent use (all p < 0.001). Logistic regression showed that living with overweight/obesity was associated with male sex, being treated for cardiorenal therapies, depression, diabetes duration, and total daily insulin doses.Conclusions: Overweight or obesity affects over half of adult PWT1D in the Canadian BETTER registry and is associated with higher HbA1c levels, higher total daily insulin doses, more chronic diabetes complications and noninsulin adjunctive agent use, a worse cardiometabolic profile, and lower hypoglycemia frequency.


  • Syndromes drépanocytaires majeurs pédiatriques et troubles cognitifs

    by Marie-Line Nicoleau, Philippe Allain, Lydia Divialle-Doumdo, Scylia Alexis-Fardini, Maryse Étienne-Julan-Otto, Benoît Tressières, Vanessa Tarer, Erwan Codron, Marie Petrat

  • Open Access

    Consequences of In Utero Zika Virus Exposure and Adverse Pregnancy and Early Childhood Outcomes: A Prospective Cohort Study

    by Rebecca Grant, Olivier Flechelles, Narcisse Elenga, Benoît Tressières, Stanie Gaete, Jean-Christophe Hebert, Bruno Schaub, Felix Djossou, Adeline Mallard, Lucetta Delver, et al.

    We aimed to describe adverse pregnancy outcomes among women who had symptomatic, RT-PCR-confirmed ZIKV infection and early childhood outcomes among their infants. We enrolled pregnant women with symptomatic, RT-PCR-confirmed ZIKV infection in a prospective cohort study, and their infants in a prospective pediatric cohort study. We defined adverse pregnancy and early childhood outcomes based on selected neurologic, ophthalmologic, auditory, musculoskeletal, and anthropometric abnormalities. We used RT-PCR and serologic tests to determine the ZIKV infection status of the child. Between 10 March and 24 November 2016, we enrolled 546 pregnant women with RT-PCR-confirmed ZIKV infection. The overall risk of adverse pregnancy and early childhood outcomes possibly related to in utero ZIKV exposure was 15.7% (95% CI: 12.8–19.0), distributed as follows: 3.6% (95% CI: 2.3–5.6) severe sequelae or fatality; 2.7% (95% CI: 1.6–4.5) major abnormalities; 9.4% (95% CI:7.1–12.2) mild abnormalities. The risk of severe sequelae or fatality was higher when ZIKV infection occurred during the first trimester (7.0%), compared to the second (2.7%) or third trimester (1.4%) (p = 0.02). Among the infants for whom ZIKV infection status could be determined, the vertical transmission rate was 3.0% (5/167) (95% CI: 1.1–7.2). Among pregnant women with symptomatic, RT-PCR-confirmed ZIKV infection, severe or major pregnancy or early childhood outcomes were present in 6.3% of fetuses and infants. Severe outcomes occurred more frequently in fetuses and infants whose mothers had been infected in the first trimester.


  • Open Access

    Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib

    by Livia Claude, Frédéric Martino, Patricia Hermand, Bassel Chahim, Pierre‐Marie Roger, Marie de Bourayne, Yohann Garnier, Benoit Tressieres, Yves Colin, Caroline Le Van Kim, et al.


  • Simultaneous exposure to both Zika virus and household insecticides during pregnancy, and fetal growth and infant developmental behavior outcomes at 18 months, in Guadeloupe

    by M. Kadawathagedara, G. Muckle, S. Cordier, L. Michineau, B. Tressieres, A. Mallard, L. Kovacic, L. Multigner, P. Quénel, C. Chevrier


  • Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients

    by H. Chaumont, E. Meppiel, E. Roze, B. Tressières, T. de Broucker, A. Lannuzel